Clinical Study

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating The Use Of Adjuvant Endocrine Therapy +/- One Year Of Everolimus In Patients With High-Risk, Hormone Receptor-Positive And Her2/Neu Negative Breast Cancer

Posted Date: May 17, 2018

  • Investigator: John Morris
  • Specialties: Hematology/Oncology, Oncology
  • Type of Study: Drug

This study is to see whether treatment with everolimus plus hormone treatment after chemotherapy will increase the time without patients cancer returning. The current standard treatment after chemotherapy is hormone treatment alone. Everolimus is currently approved for the treatment of advanced or metastatic kidney cancer, it is considered investigational for breast cancer patients. Patients will get hormone treatment with either everolimus or with placebo.

Criteria:

Eligible Patients Must Have Hormone Responsive Breast Cancer That Has Already Been Removed By Surgery And Have Completed Any Required Chemotherapy Or Radiation

Keywords:

Brca, Breast Cancer, Her2, Metastatic Breast Cancer, S1207

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.